{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:41:46Z","timestamp":1792172506461,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971003"],"award-info":[{"award-number":["81971003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171406"],"award-info":[{"award-number":["82171406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key project of research and development plan of Shaanxi Province","award":["2018SF-086"],"award-info":[{"award-number":["2018SF-086"]}]},{"name":"Key project of basic natural science research program of Shaanxi Province","award":["2019JZ-18"],"award-info":[{"award-number":["2019JZ-18"]}]},{"name":"Tangdu hospital innovation development foundation","award":["2018QYTS010"],"award-info":[{"award-number":["2018QYTS010"]}]},{"name":"Tangdu hospital innovation development foundation","award":["2019QYTS002"],"award-info":[{"award-number":["2019QYTS002"]}]},{"name":"Tangdu hospital clinical research project","award":["2021LCYJ040"],"award-info":[{"award-number":["2021LCYJ040"]}]},{"name":"Tangdu hospital foundation for social recruitment talent","award":["2021SHRC011"],"award-info":[{"award-number":["2021SHRC011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00415-022-11048-4","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T12:18:43Z","timestamp":1646309923000},"page":"4229-4240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis"],"prefix":"10.1007","volume":"269","author":[{"given":"Ying","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-feng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-1551","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"issue":"26","key":"11048_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"11048_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116648","volume":"410","author":"J Morren","year":"2020","unstructured":"Morren J, Li Y (2020) Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci 410:116648. https:\/\/doi.org\/10.1016\/j.jns.2019.116648","journal-title":"J Neurol Sci"},{"issue":"4","key":"11048_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s00415-019-09667-5","volume":"267","author":"J Rath","year":"2020","unstructured":"Rath J, Brunner I, Tomschik M et al (2020) Frequency and clinical features of treatment-refractory myasthenia gravis. J Neurol 267(4):1004\u20131011. https:\/\/doi.org\/10.1007\/s00415-019-09667-5","journal-title":"J Neurol"},{"key":"11048_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fneur.2020.00981","volume":"11","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, Antozzi C (2020) From traditional to targeted immunotherapy in myasthenia gravis: prospects for research. Front Neurol 11:981. https:\/\/doi.org\/10.3389\/fneur.2020.00981","journal-title":"Front Neurol"},{"issue":"2","key":"11048_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM et al (2018) Treatment of myasthenia gravis. Neurol Clin 36(2):311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"issue":"4","key":"11048_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"issue":"1","key":"11048_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"issue":"2","key":"11048_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P et al (2018) B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 57(2):172\u2013184. https:\/\/doi.org\/10.1002\/mus.25973","journal-title":"Muscle Nerve"},{"issue":"2","key":"11048_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/25785826.2020.1724756","volume":"43","author":"K Takata","year":"2020","unstructured":"Takata K, Kinoshita M, Mochizuki H et al (2020) Antigen specific B cells in myasthenia gravis patients. Immunol Med 43(2):65\u201371. https:\/\/doi.org\/10.1080\/25785826.2020.1724756","journal-title":"Immunol Med"},{"issue":"9","key":"11048_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","volume":"16","author":"B Sun","year":"2020","unstructured":"Sun B, Ramberger M, O\u2019Connor KC et al (2020) The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nat Rev Neurol 16(9):481\u2013492. https:\/\/doi.org\/10.1038\/s41582-020-0381-z","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"11048_CR11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA et al (2020) Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77(8):974\u2013981. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"issue":"4","key":"11048_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG et al (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91(4):392\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2019-322606","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"11048_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1212\/wnl.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E, Massey JM, Tucker-Lipscomb B et al (2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56(1):97\u201399. https:\/\/doi.org\/10.1212\/wnl.56.1.97","journal-title":"Neurology"},{"issue":"7","key":"11048_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP et al (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489. https:\/\/doi.org\/10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"issue":"2","key":"11048_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21016","volume":"38","author":"LL Mullins","year":"2008","unstructured":"Mullins LL, Carpentier MY, Paul RH et al (2008) Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 38(2):947\u2013956. https:\/\/doi.org\/10.1002\/mus.21016","journal-title":"Muscle Nerve"},{"issue":"3","key":"11048_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20(3):179\u2013199. https:\/\/doi.org\/10.1038\/s41573-020-00092-2","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"11048_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","volume":"39","author":"L Bergantini","year":"2020","unstructured":"Bergantini L, d\u2019Alessandro M, Cameli P et al (2020) Effects of rituximab therapy on B cell differentiation and depletion. Clin Rheumatol 39(5):1415\u20131421. https:\/\/doi.org\/10.1007\/s10067-020-04996-7","journal-title":"Clin Rheumatol"},{"key":"11048_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418761697","volume":"11","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN et al (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697. https:\/\/doi.org\/10.1177\/1756286418761697","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"11048_CR19","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","volume":"27","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos A, Noury JB, Genestet S et al (2020) Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol 27(11):2277\u20132285. https:\/\/doi.org\/10.1111\/ene.14391","journal-title":"Eur J Neurol"},{"issue":"7","key":"11048_CR20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","volume":"266","author":"N Singh","year":"2019","unstructured":"Singh N, Goyal V (2019) Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study. J Neurol 266(7):1596\u20131600. https:\/\/doi.org\/10.1007\/s00415-019-09296-y","journal-title":"J Neurol"},{"key":"11048_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419871187","volume":"12","author":"K Choi","year":"2019","unstructured":"Choi K, Hong YH, Ahn SH et al (2019) Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419871187. https:\/\/doi.org\/10.1177\/1756286419871187","journal-title":"Ther Adv Neurol Disord"},{"key":"11048_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577528","volume":"354","author":"H Li","year":"2021","unstructured":"Li H, Huang Z, Jia D et al (2021) Low-dose rituximab treatment for new-onset generalized myasthenia gravis. J Neuroimmunol 354:577528. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577528","journal-title":"J Neuroimmunol"},{"issue":"12","key":"11048_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","volume":"26","author":"C Zhang","year":"2020","unstructured":"Zhang C, Bu B, Yang H et al (2020) Immunotherapy choice and maintenance for generalized myasthenia gravis in China. CNS Neurosci Ther 26(12):1241\u20131254. https:\/\/doi.org\/10.1111\/cns.13468","journal-title":"CNS Neurosci Ther"},{"key":"11048_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","volume":"85","author":"T Li","year":"2021","unstructured":"Li T, Zhang GQ, Li Y et al (2021) Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis. J Clin Neurosci 85:6\u201312. https:\/\/doi.org\/10.1016\/j.jocn.2020.11.043","journal-title":"J Clin Neurosci"},{"issue":"3","key":"11048_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.26790","volume":"61","author":"J Lu","year":"2020","unstructured":"Lu J, Zhong H, Jing S et al (2020) Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis. Muscle Nerve 61(3):311\u2013315. https:\/\/doi.org\/10.1002\/mus.26790","journal-title":"Muscle Nerve"},{"issue":"7","key":"11048_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","volume":"3","author":"D Anderson","year":"2016","unstructured":"Anderson D, Phan C, Johnston WS et al (2016) Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol 3(7):552\u2013555. https:\/\/doi.org\/10.1002\/acn3.314","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"11048_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","volume":"74","author":"KR Robeson","year":"2017","unstructured":"Robeson KR, Kumar A, Keung B et al (2017) Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 74(1):60\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4190","journal-title":"JAMA Neurol"},{"issue":"8","key":"11048_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81(8):710\u2013713. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a1aac7","journal-title":"Neurology"},{"key":"11048_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10362-z","author":"CG Chisari","year":"2021","unstructured":"Chisari CG, Sgarlata E, Arena S et al (2021) Rituximab for the treatment of multiple sclerosis: a review. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10362-z","journal-title":"J Neurol"},{"key":"11048_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.595984","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Li C, Duan FJ et al (2021) Case report: repeated low-dose rituximab treatment is effective in relapsing neuro Behcet\u2019s disease. Front Neurol 12:595984. https:\/\/doi.org\/10.3389\/fneur.2021.595984","journal-title":"Front Neurol"},{"key":"11048_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","volume":"311","author":"S Jing","year":"2017","unstructured":"Jing S, Song Y, Song J et al (2017) Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. J Neuroimmunol 311:14\u201321. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.021","journal-title":"J Neuroimmunol"},{"issue":"11","key":"11048_CR32","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00415-007-0593-9","volume":"254","author":"A Chan","year":"2007","unstructured":"Chan A, Lee DH, Linker R et al (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254(11):1604\u20131606. https:\/\/doi.org\/10.1007\/s00415-007-0593-9","journal-title":"J Neurol"},{"issue":"5","key":"11048_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","volume":"8","author":"MN Meriggioli","year":"2012","unstructured":"Meriggioli MN, Sanders DB (2012) Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 8(5):427\u2013438. https:\/\/doi.org\/10.1586\/eci.12.34","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11048-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T12:28:32Z","timestamp":1658147312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11048-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["11048"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11048-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We provided patients detailed information\u00a0about\u00a0the disease, and obtained the consent of the patients to repeated low-dose RTX treatment. We have also reported to the Ethical Committee of Tangdu Hospital, Fourth Military Medical University, and obtained the approval from the committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained written informed consent from both patients for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}